Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Yuan X, Marcano DC, Shin CS, Hua X, Isenhart LC, Pflugfelder SC, et al
Br J Clin Pharmacol
Mean monthly headache days reduced significantly in the exenatide arm ( 7.7 days) compared to the placebo arm (-1.5 days), with no significant difference between exenatide and placebo groups at 12 weeks
VESPER-3: the monthly maintenance experiment Pfizer describes VESPER-3 as an ongoing Phase 2b study evaluating monthly maintenance dosing in adults with obesity/overweight without type 2 diabetes
1 The APA emphasizes the importance of mental health professionals to help patients navigate body image changes, identity shifts, stigma, and evolving relationships with food during treatment
Unfortunately, our database did not include information regarding treatment duration, distribution of time from index date to treatment initiation, the percentage of covered time or whether both medications were taken concurrently in patients receiving combination therapy
US$ 24.72
US$ 28.47
US$ 29.85
US$ 20.83
US$ 26.29
US$ 24.44
US$ 20.81
US$ 27.66
US$ 27.09
US$ 25.55
